Clinical Trial Detail

NCT ID NCT03821792
Title Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

prostate adenocarcinoma

Therapies

Abiraterone + Apalutamide + Prednisone

Age Groups: adult senior

No variant requirements are available.